Updated Canaccord report attached.
Excellent uptake. Production in Costa Rica to commence Sept 2017. Smaller capacity in the meantime. Growth potential appears strong in long term. Well funded. Tight register. (IMO) Looks a good investment company for at least 2- 5 years.
I still expect a takeover from one of the breast implant companies once the product is established - great sales synergies in terms of medical rep team and branded product use (ie use the expander and breast implant from the same company - this is very easy for the surgeon as does not need 2 separate reps to organise). A take-over should be very profitable for shareholders. Its just about timing.
Tyremen
Ann: Appendix 4C, page-13
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AXP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.824M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $4.303K | 2.151M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 40085905 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 91807222 | 63 |
View Market Depth
| Last trade - 10.57am 04/12/2024 (20 minute delay) ? |
| AXP (ASX) Chart |
